8-K
filed November 8, 2022, 6:59 PM ET
ticker MNKD
CIK 0000899460
earnings
confidence high
sentiment positive
materiality 0.75
MannKind Q3 2022 revenue $32.8M, up 48% YoY; net loss widens to $14.4M
MANNKIND CORP
2022-Q3 EPS reported
-$0.27
revenue$63,711,000
- Total revenues $32.8M (+48% YoY); Afrezza net revenue $10.8M (+11%), V-Go net revenue $5.4M.
- Tyvaso DPI royalties $6.2M; collaborations and services $10.3M including manufacturing revenue.
- Net loss $14.4M ($0.06/sh) vs $4.4M loss in Q3 2021; higher SG&A and interest expense.
- Afrezza gross margin 81% (up from 61%); V-Go gross margin 46%.
- Cash and investments $177.8M; nine-month net loss $69.5M ($0.27/sh).
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
MANNKIND CORP reported the third quarter ended September 30, 2022 results: revenue $32.8 million, net income $14.4 million, EPS $0.06 per share.
- Period
- the third quarter ended September 30, 2022
- Revenue
- $32.8 million
- Net income
- $14.4 million
- EPS
- $0.06 per share
- Result
- reported results
Exact text from the filing
--- mnkd-ex991_6.htm EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2022 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 9:00 a.m. (ET) • 3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 2021 • 3Q 2022 Royalties from Tyvaso DPI of $6.2 million • 3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
MANNKIND CORP reported the nine months ended September 30, 2022 results: revenue $63.7 million.
- Period
- the nine months ended September 30, 2022
- Revenue
- $63.7 million
- Result
- reported results
Exact text from the filing
Total revenues were $63.7 million for the nine months ended September 30, 2022
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.